Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
Year: 2004
Type: article
Study design: Clinical Trial
Source: Blood
Authors: M. Alsina, Rafael Fonseca, Edward F Wilson, A Nelida Belle, Elvira Gerbino, Tammy Price-Troska, Rose M Overton, Gregory Ahmann, Laura M Bruzek, Alex A Adjei, Scott H Kaufmann, John J Wright, Daniel Sullivan, Benjamin Djulbegovic, Alan B Cantor, Philip R Greipp, William S Dalton, Saïd M Sebti
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2155167738
